Tag: Methylsulfonamide AMPA potentiator

  • Farampator (CX-691)

    Methylsulfonamide AMPA potentiator

    An Organon/Schering-Plough ampakine (CX-691) that reached Phase 2 in major depressive disorder and Alzheimer disease.

    Abstract

    Farampator (CX-691, ORG-24448; CAS 211735-76-1; molecular formula C16H22N2O3S; molecular weight 322.42) is a methylsulfonamide-class AMPA receptor positive allosteric modulator developed by Cortex Pharmaceuticals and licensed to Organon (subsequently Schering-Plough, then Merck). The compound advanced through Phase 2 trials in major depressive disorder, Alzheimer disease, and adult ADHD with mixed results; the development program was discontinued after the Schering-Plough acquisition by Merck. Mechanism is AMPA receptor positive allosteric modulation with characteristics intermediate between the early CX-516 class and the later sustained-action ampakines. Pharmacokinetics: plasma half-life approximately 5 to 6 hours; oral bioavailability adequate. The compound is sold as a research chemical with limited availability. The clinical evidence base in depression specifically is interesting: rapid antidepressant-like effects analogous to those seen with ketamine were observed in Phase 2, suggesting the ampakine mechanism may share some clinical pharmacology with NMDA-blocking rapid antidepressants.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.